Treatment of Refractory Hematospermia With Finasteride: A Prospective Placebo-Controlled Study
October 2023
in “
Bangladesh journal of urology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → 
Studysummary This study in Bangladesh reports that 81% of patients with refractory idiopathic hematospermia showed remission after three months of finasteride treatment, significantly higher than the 27% remission rate in the placebo group, with results sustained for some time after stopping the medication.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This prospective placebo-controlled study evaluated the efficacy of finasteride in treating refractory idiopathic hematospermia in 22 patients. The study found that 81% of patients treated with finasteride experienced cessation of hematospermia after 3 months, compared to 27% in the placebo group (P = 0.03). Remission occurred in 45% of finasteride-treated patients within 1 month, and although hematospermia recurred in some patients after stopping treatment, a significant decrease in bleeding frequency and amount was observed. The study concludes that a 3-month finasteride treatment significantly cures hematospermia without undesirable side effects.
